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Abstract Since 2008, the direct-acting oral anticoagulants
(DOACs) have expanded the therapeutic options of car-
diovascular diseases with recognized clinical and epi-
demiological impact, such as non-valvular atrial fibrillation
(NVAF) and venous thromboembolism (VTE), and also in
the preventive setting of orthopedic surgical patients. The
large body of evidence, not only from pivotal clinical trials
but also from ‘real-world’ postmarketing observational
findings (e.g. analytical epidemiological studies and reg-
istry data) gathered to date allow for a first attempt at
verifying a posteriori whether or not the pharmacological
advantages of the DOACs actually translate into thera-
peutic innovation, with relevant implications for clinicians,
regulators and patients. This review aims to synthesize the
risk–benefit profile of DOACs in the aforementioned con-
solidated indications through an ‘evidence summary’
approach gathering the existent evidence-based data, par-
ticularly systematic reviews with meta-analyses of ran-
domized controlled trials, as well as observational studies,
comparing DOACs with vitamin K antagonists. Clinical
evidence will be discussed and compared with major
international guidelines to identify whether an update is
needed. Controversial clinically relevant safety issues will
be also examined in order to highlight current challenges
and unsettled questions (e.g. actual bleeding risk in sus-
ceptible populations). It is anticipated that the large number
of publications on NVAF or VTE (44 systematic reviews
with meta-analyses and 12 observational studies retained in
our analysis) suggests the potential existence of overlap-
ping studies and calls for common criteria to qualitatively
and quantitatively assess discordances, thus guiding future
research.
Key Points
Our systematic search retrieved 44 systematic
reviews and 12 observational studies comparing
direct-acting oral anticoagulants (DOACs) with
vitamin K antagonists (VKAs) in non-valvular atrial
fibrillation and/or venous thromboembolism patients,
thus indicating the need to formally assess actual
overlapping studies.
This body of evidence corroborates the general
consensus that, overall, DOACs are comparable to
VKAs in terms of safety, efficacy and effectiveness,
and unequivocally indicates a consistent and
clinically relevant reduced risk (more than 50 %) of
intracranial bleeding.
A number of unsettled questions still require
dedicated investigation by post-authorization safety
studies (including head-to-head comparisons),
particularly the actual magnitude of gastrointestinal
bleeding risk in special populations, the impact of
renal impairment on the risk–benefit profile of
DOACs, and the risk of liver injury.
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1 Introduction
Anticoagulant therapy represents the mainstay for the pre-
vention and treatment of venous thromboembolism (VTE),
comprising deep vein thrombosis (DVT) and pulmonary
embolism (PE) [1], as well as for the prevention of stroke in
patients with atrial fibrillation (AF) [2–4]. For decades,
heparins [especially low-molecular-weight heparins
(LMWHs)] and vitamin K antagonists (VKAs; especially
warfarin) have been the pillar of anticoagulant therapy.
Recently, the drug discovery paradigm has shifted
towards rational design following a target-based approach,
and resulted in the development of oral agents that directly
inhibit the activity of thrombin [direct thrombin inhibitors
(DTIs), such as dabigatran] or activated factor X (factor Xa
inhibitors, such as rivaroxaban, apixaban, edoxaban), now
referred to as direct-acting non-vitamin K oral anticoagu-
lants (DOACs) [5–7].
Apart from the first-in-class drug ximelagatran, with-
drawn early from the market because of liver toxicity, the
launch of DOACs dates back to 2008 when dabigatran was
licensed by the European Medicines Agency (EMA)
through a priority review process based on results from a
single phase III trial for the prevention of VTE in patients
undergoing major orthopedic surgery (i.e. elective total hip
replacement surgery or total knee replacement surgery).
Dabigatran was also the first DOAC to receive approval
from the EMA in October 2010 for stroke prevention in
non-valvular AF (NVAF). Edoxaban, the latest DOAC to
be approved, received marketing authorization from the
EMA and Food and Drug Administration (FDA) in early
2015, both for NVAF and for the treatment (not preven-
tion) of DVT and PE following 5–10 days of initial therapy
with a parenteral anticoagulant. Notably, rivaroxaban is the
only oral anticoagulant to receive specific indication in
Europe for the prevention of recurrent atherothrombotic
events in patients with acute coronary syndrome (ACS).
Discussing the comparative clinical pharmacology of
DOACs versus VKAs, as well as their pros and cons, is
beyond the aim of this review; for details, the reader may
refer to recent review articles [8–10]. The DOACs have
favorable pharmacological properties, which contributed to
their relatively fast introduction in clinical practice,
including predictable dose–response curve with fixed doses
for most patients (minimizing the need for dose adjust-
ment), and limited food and drug interactions. However,
the variability in renal excretion among DOACs, the lack
of widely available laboratory tests for measuring their
anticoagulant activity, when required, and the currently
limited clinical experience in case of overdose and/or
severe bleeding should not be overlooked.
A large body of evidence, not only from pivotal clinical
trials, but also from ‘real-world’ postmarketing observa-
tional findings (e.g. analytical epidemiological studies and
registry data) has accrued in recent years and the question
arises whether or not these theoretical pharmacological
advantages of DOACs actually translate into therapeutic
innovation, i.e. if this class of medicines represents just an
additional therapeutic option or a real breakthrough [11].
In this context, our aim was to (i) summarize evidence
on the efficacy, effectiveness, and safety of DOACs in
established indications, namely NVAF and VTE, compared
with VKAs; and (ii) highlight current challenges and future
perspectives on the actual role of DOACs in these settings.
This is also justified in light of the ongoing debate on
whether or not results of randomized controlled trials
(RCTs) can be safely transferred to the general population
[12, 13].
2 Methods
This overview adopts an ‘evidence summary’ approach
with the aim of assessing the risk–benefit profile of
DOACs. This will be achieved by analyzing and summa-
rizing the existent body of evidence, in particular using
systematic reviews with meta-analyses of RCTs (i.e. the
highest level/strength of evidence), as well as observational
studies comparing DOACs with VKAs. Although rapid
reviews cannot be formally considered as systematic
analysis, they may share quality and reproducibility of
systematic reviews (provided that the research question and
criteria for study selection and appraisal are specified a
priori) with the additional benefit of a descriptive sum-
mary/categorization of the data, thus highlighting areas of
further research [14, 15].
To this end, and keeping in mind the importance of
analyzing the best available evidence, we systematically
performed a prespecified search strategy in MEDLINE/
PubMed to extract the following.
(i) Systematic reviews of RCTs or observational studies,
published as of 30 September 2015 (effective date the
search was performed). Detailed criteria for article
retrieval and eligibility are provided as supplementary
material (electronic supplementary Table 1). We
decided to include only direct comparisons between
DOACs and VKAs and, therefore, exclude indirect
network meta-analyses (NMAs) because their actual
value and methodological quality is still a matter of
debate [16]. In addition, a critical appraisal of 11
NMAs on the efficacy and safety of DOACs in NVAF
has recently been published by the International
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Society of Pharmacoeconomics and Outcomes
Research [17].
(ii) Observational studies (used as a proxy of real-world
data), published as of 31 January 2016. Detailed
criteria for article retrieval and eligibility are pro-
vided as supplementary material (electronic supple-
mentary Table 2). Considering the aim of assessing
the safety and effectiveness in clinical practice, we
selected analytical studies providing a clear epidemi-
ological measure [i.e. relative risk, risk ratio (RR),
odds ratio (OR)], excluding descriptive studies deal-
ing with the management and treatment of AF and
other forms of registry.
Article assessment for eligibility, data extraction and
interpretation, as well as quality evaluation, were per-
formed in blind by ER and MB through common criteria.
All outcomes reported in the different studies were ana-
lyzed, regardless of clinical relevance and severity (i.e.
both fatal and non-serious events were considered). Both
efficacy (e.g. stroke, recurrent VTE, mortality) and safety
[e.g. intracranial hemorrhage (ICH), major/fatal bleeding,
gastrointestinal bleeding, renal/hepatic safety] endpoints
were then extracted. Disagreements were solved by con-
sensus. For both systematic reviews and observational
studies, the most adjusted estimates were extracted. In case
different data were provided for different doses, results
from the highest dose were selected. For systematic
reviews with meta-analysis, heterogeneity was also
extracted and considered for the overall assessment.
In particular, the following prespecified criteria were
applied to extracted data to assess individual outcome
recorded by systematic review/observational study (i.e.
without considering the conclusions provided by the
authors in the original full text):
• Favor DOACs (:): OR, RR, or hazard ratio (HR)
extracted from relevant studies were statistically sig-
nificant for DOACs, with low-to-moderate heterogene-
ity (i.e. I2\ 70 % for meta-analysis);
• Favor VKAs (;): OR, RR or HR extracted from
relevant studies were statistically significant for VKAs,
with low-to-moderate heterogeneity (i.e. I2\ 70 % for
meta-analysis);
• Neutral ($): OR, RR or HR extracted from relevant
studies were not statistically significant, or high
heterogeneity was reported (i.e. I2[ 70 % for meta-
analysis).
Therefore, a study counts as many-fold as the number of
outcomes/indications/DOACs/doses investigated.
Because multiple systematic reviews with meta-analyses
emerged, we further assessed their quality by individually
applying the 11 items of the validated AMSTAR tool [18].
We decided to exclude item number 8 (‘‘Was the scientific
quality of the included studies used appropriately in for-
mulating conclusion?’’) from the evaluation for the fol-
lowing reasons: (i) only rarely was the scientific quality
considered to draw conclusions and formulate recommen-
dations in the majority of systematic reviews (with the
exception of Cochrane reviews), especially due to the
reduced number of studies; (ii) we did not use the con-
clusions posted in the manuscript by the authors in the text,
instead we interpreted reported results according to our
methodological criteria. Therefore, the maximum score
was 10. Detailed criteria and final quality assessment are
provided as supplementary material (electronic supple-
mentary Table 3).
3 Results
Overall, from the initial 722 articles, 44 systematic reviews
with meta-analysis [19–61] and 12 observational studies
[62–73] were finally retained. A synopsis of the overall
assessment is presented in Tables 1 and 2, whereas the full
list of studies with relevant details are provided as sup-
plementary material (electronic supplementary Tables 1
and 2).
The majority of systematic reviews addressed both effi-
cacy and safety, whereas 13/44 focused only safety (mainly
intracranial and gastrointestinal bleeding). Half of the
included studies (21/44) enrolled AF patients only, 9/44
were carried out on VTE patients (3 in VTE patients with
cancer) only, and 14/44 analyzed both AF and VTE popu-
lations. Eleven systematic reviews were specifically
designed to evaluate one single endpoint, mainly safety
outcomes: liver injury, renal damage, intraocular bleeding,
ICH, drug tolerability, gastrointestinal bleeding, and
myocardial infarction. A large proportion of systematic
reviews (37/44) collected data from RCTs, four from
observational studies and three from both randomized and
non-randomized studies; these seven systematic reviews
were conducted to evaluate the safety and efficacy of
DOACs in the setting of AF ablation. The largest proportion
of systematic reviews was published in 2014–2015 (30/44),
both in general (e.g. PLoS ONE, Lancet, BMJ, Annals of
Internal Medicine) and specialized journals (e.g. Heart), and
in the Cochrane Database of Systematic Reviews archive.
Major bleeding, fatal bleeding and clinically relevant
bleeding were the most frequently investigated safety
outcomes, whereas ischemic stroke/systemic embolism
were the preferred efficacy endpoints. With regard to
special populations, three systematic reviews were per-
formed to assess VTE risk in patients with cancer, whereas
two studies analyzed the impact of renal injury on the risk–
benefit profile of DOACs.
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The quality of systematic reviews was ranked ‘high’ for
33 studies (i.e. the AMSTAR score was C9/10 for 75 % of
the studies), of which 17 received the maximum score. The
majority (76 %) analyzed more than one endpoint, with
seven systematic reviews assessing at least four outcomes
and documenting clinical benefit in terms of efficacy and
safety issues. The inability to capture grey literature and
evaluate the quality of included studies were the main
reasons affecting the final score (electronic supplementary
Table 3).
Observational studies were mainly performed on effec-
tiveness and safety (7/12), rather than only on safety (5/12).
Half analyzed dabigatran, four analyzed dabigatran and
rivaroxaban, and two analyzed rivaroxaban only. The
majority (9/12) were performed only on patients with AF,
2/12 were performed on both AF and VTE populations, and
Table 1 Synopsis of the evidence-based evaluation of DOACs in consolidated therapeutic indications (NVAF and DVT/PE): systematic reviews





Best effect (95 % CI)a Worst effect (95 % CI)b
: $ ;
Safety Major bleeding, fatal bleeding, clinically
relevant bleeding




Clinically relevant non-major bleeding 3c 5d RR 0.58 (0.48–0.70)
(dabigatran)




Intracranial hemorrhage 13 RR 0.43 (0.37–0.50) (in
patients with AF or
venous
thromboembolism)









(I2 = 91 %)
Other bleeds (e.g. ocular) and safety issues (e.g.
discontinuation due to ADR, tolerability)






Myocardial infarction 9 3 OR 0.87 (0.73–1.05) (in
patients with AF)
RR 2.55 (1.14–5.69) (in
patients with venous
thomboembolism)





RR 0.82 (0.56–1.18) (liver
injury)
RR 1.43 (0.63–3.24) (renal
impairment,
rivaroxaban)
Efficacy Ischemic stroke/systemic embolism (including
composite outcomes and hemorrhagic stroke,
thromboembolic events, other cardiovascular
events)
13 10 2 RR 0.77 (0.70–0.86)
(NNT = 137)
OR 3.94 (1.54–10.08) (in
AF ablation based on
observational studies)
Mortality (all-cause or vascular death) 9 11 RR 0.88 (0.81–0.94)
(cardiovascular
mortality)











A study counts as many-fold as the number of outcomes/indications/DOACs investigated
DOACs direct-acting oral anticoagulants, NVAF non-valvular atrial fibrillation, DVT deep vein thrombosis, PE pulmonary embolism, ADR
adverse drug reaction, AF atrial fibrillation, NNT number needed to treat, OR odds ratio, RR risk ratio, ULN upper limit of normal, : indicates
favors DOACs, ; indicates favors VKAs, $ indicates neutral (as effective/safe as VKAs)
a Based on the upper limit of the confidence intervals
b Based on the lower (efficacy outcome) or upper (safety outcome) limit of the confidence intervals
c One study highlighted a favorable effect in the subgroup analysis for dabigatran
d One study analyzed clinically relevant bleeding ? clinically relevant non-major bleeding
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only one was performed on VTE patients only. Notably,
only 2/12 studies were designed to assess a single outcome,
i.e. gastrointestinal bleeding, which was also the most
frequently investigated endpoint. A cohort study design
was undertaken in all studies.
According to systematic reviews of RCTs, DOACs
reduced the risk of ICH by approximately 50 % [data are
consistent across the different meta-analyses, with the
largest estimate being RR 0.43, 95 % confidence interval
(CI) 0.37–0.50], whereas observational studies found an
even larger benefit [adjusted HR (adjHR) 0.08, 95 % CI
0.01–0.40]. With regard to gastrointestinal bleeding, sys-
tematic reviews were in agreement overall and did not find
a statistically significant increased risk; only one study
documented a favorable effect compared with VKAs (RR
0.64, 95 % CI 0.41–0.99) in VTE patients with cancer.
Observational studies instead demonstrated, in some cases,
an increased risk (HR 1.85, 95 % CI 1.64–2.07). A similar
pattern was observed for major bleeding, fatal bleeding and
clinically relevant bleeding. Apart from bleeding issues,
different systematic reviews assessed the potential risk of
myocardial infarction, liver and renal injury. For myocar-
dial infarction only, a statistically significant association
emerged from systematic reviews (RR 2.55, 95 % CI
1.14–5.69), although this was not confirmed by observa-
tional studies, which documented a strong protective effect
(adjHR 0.40, 95 % CI 0.21–0.70).
4 Discussion
We collapsed key findings from previous systematic
reviews and observational studies, an approach that is only
rarely performed in the literature [74]. In fact, the majority
of recent meta-analyses actually neglect previous system-
atic reviews on the same topic [75]. Our overview retained
44 systematic reviews and 12 observational studies com-
paring DOACs with VKAs in NVAF and/or VTE patients,
thus suggesting the potential existence of overlapping
studies (i.e. the different systematic reviews may meta-
Table 2 Synopsis of the evidence-based evaluation of DOACs in consolidated therapeutic indications (NVAF and DVT/PE): observational





Best effect (95 % CI)a Worst effect (95 % CI)b
: $ ;
Safety Major bleeding, fatal
bleeding
2c 4 2 adjHR 0.59 (0.45–0.78)
(dabigatran 150 mg in VKA-
experienced patients)
HR 1.89 (1.54–2.32) (dabigatran,
in users of antiplatelet agents)
Intracranial hemorrhage 5d 1 adjHR 0.08 (0.01–0.40)
(dabigatran 150 mg)
HR 1.17 (0.66–2.05) (rivaroxaban)
Gastrointestinal bleeding 2e 8 3 HR 0.60 (0.37–0.93) (dabigatran
110 mg in VKA-naı¨ve patients)
HR 2.91 (1.65–4.81) (rivaroxaban,
aged[75 years)
Other (e.g. hospitalization
due to bleeding, all
bleeding events)
1 6 adjHR 0.86 (0.79–0.93)
(dabigatran 150 mg,
hospitalization)
HR 0.98 (0.64–1.51) (rivaroxaban,
hospitalization)
















4 2 HR 0.33 (0.21–0.53) (rivaroxaban,




A study counts as many-fold as the number of outcomes/indications/DOACs/doses investigated
DOACs direct-acting oral anticoagulants, NVAF non-valvular atrial fibrillation, DVT deep vein thrombosis, PE pulmonary embolism, adjHR
adjusted hazard ratio, HR hazard ratio, AF atrial fibrillation, VKA vitamin K antagonist, : indicates favors DOACs, ; indicates favors VKAs,$
indicates neutral (as effective/safe as VKAs)
a Based on the upper limit of the confidence intervals
b Based on the lower (efficacy outcome) or upper (safety outcome) limit of the confidence intervals
c For dabigatran 110 mg in VKA-naı¨ve patients
d All for dabigatran
e For dabigatran 110 mg and dabigatran 110 mg in VKA-naı¨ve patients
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analyze the same original studies and the same outcomes),
which require formal assessment to guide future research.
The evaluation of this aspect requires an a priori study
design and was beyond the aim of the present analysis.
This body of evidence (i) corroborates the general
consensus that DOACs are, overall, comparable with
VKAs in terms of safety, efficacy and effectiveness; (ii)
highlights that results from meta-analysis of RCTs are in
line with those from observational studies, both in terms of
the overall direction of the effects and their estimates [76];
and (iii) unequivocally indicates a consistent and clinically
relevant reduced risk of ICH, which emerged during pre-
registration trials, was confirmed in systematic reviews,
and was further corroborated by observational studies. All
studies documenting this protective effect relate to dabi-
gatran, whereas the only matched cohort study reporting no
statistically significant protective effect on ICH (HR 1.17,
95 % CI 0.66–2.05) compared rivaroxaban with warfarin.
The latest meta-analysis of observational studies on dabi-
gatran (not included in our analysis) corroborated these
findings by pooling seven cohort studies (HR 0.44, 95 %
CI 0.34–0.59, I2 = 64 % for dabigatran 150 mg) [77]. The
mechanism behind a reduced ICH risk is still largely
unknown, although in vivo studies pointed out that the
potential anti-inflammatory properties of dabigatran may
partially explain the observed clinical benefit [78, 79].
With regard to other bleeding complications, the actual
risk and/or clinical benefit of DOACs appears to still be
unresolved (lack of consistency among studies), which is
the case for gastrointestinal, major and fatal bleeding. As
expected, compared with systematic reviews of RCTs,
observational studies documented a higher risk of gas-
trointestinal bleeding, which emerged for dabigatran
(especially at a dose of 150 mg or in patients aged
C75 years [65]) and rivaroxaban [64]. Different nation-
wide propensity-matched cohort studies reported no sta-
tistically significant differences for both drugs [70, 72], and
a favorable effect for dabigatran 110 mg was reported in
VKA-naı¨ve patients.
Beyond bleeding complications, three safety issues
deserve to be mentioned as they represent clinically
important events per se, i.e. coronary risk, liver injury and
renal impairment. As expected, our review did not identify
these rare safety signals. A recent literature review, com-
prising case reports, concluded that, while the coronary risk
(described for dabigatran) is not supported by a critical
evaluation of the evidence, the unpredictable occurrence of
liver injury and the potential for renal damage warrant a
more precise characterization and call for awareness by
clinicians (see below) [80].
With regard to efficacy, some differences exist among
the different outcomes. This is especially the case for
patients with NVAF. In this setting, some discordances
across systematic reviews emerged on ischemic stroke/
systemic embolism and mortality, whereas in patients with
VTE, DOACs were comparable with VKAs (with the
exception of one study, all were concordant in reporting a
statistically non-significant reduced risk of recurrent VTE/
PE). Notably, observational studies documented a potential
benefit of high magnitude (60 % risk reduction); however,
it is important to underline that these positive results were
derived from an industry-sponsored study on rivaroxaban
performed in NVAF patients and reporting a lower likeli-
hood of VTE events and higher persistence compared with
warfarin, despite no difference in terms of major effec-
tiveness and safety outcomes [71].
In NVAF, the place in therapy of DOACs appears
consolidated. A variety of recommendations have been
formulated by several scientific societies. Among these, the
American College of Cardiology (ACC) provided practical
algorithm-based approaches to support the management of
DOACs in clinical practice [81], and the updated European
Heart Rhythm Association (EHRA) practical guide listed
practical aspects in different common clinical scenarios
[82]. We now have the opportunity to match an anticoag-
ulant drug to the individual patient, who is unique for his/
her genetic profile, comorbid conditions, concomitant
medications, and adherence to treatment [83–86]. A sim-
plified algorithm to facilitate the selection of preferred
anticoagulant agents in AF is provided in Fig. 1.
Conversely, the precise role of DOACs in VTE is still a
matter of debate and is a clinical research priority. In fact,
the latest American College of Chest Physicians (ACCP)
guideline was the first to recommend DOACs over VKAs
for initial and long-term VTE treatment (in the absence of
cancer) [87]. Our data supported comparable efficacy and
safety of DOACs compared with VKAs [56], although the
most comprehensive meta-analysis by Adam et al. com-
pared DOACs with LMWHs (standard therapy in this set-
ting) and demonstrated that, although effective for
thromboprophylaxis after total hip or knee replacement,
their clinical benefits are marginal over LMWHs and are
offset by increased risk of major bleeding [88]. Acute-
phase management of VTE may differ depending on the
DOAC used. Dabigatran is administered after an initial
treatment with LMWHs in the acute phase, before oral
maintenance treatment with dabigatran is started. By con-
trast, rivaroxaban and apixaban are used in a single-agent
approach (i.e. there is no need for initial acute-phase
treatment with LMWHs, but they do require a dose change
between initial and maintenance phases). Notably, in a
phase III trial of rivaroxaban, the majority of patients
(84 %) received prestudy heparins for a mean duration of
1 day before starting rivaroxaban, although no remarkable
differences emerged in patients not receiving this bridge
therapy [89]. It is still uncertain whether one approach has
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a clinical advantage over another. Future research should
assess (i) the actual effectiveness of a single versus dual-
agent approach, and (ii) the optimal length of VTE therapy
and the need for extended treatment. In fact, the risk of
recurrent VTE is highest soon after the VTE event, and
declines thereafter, although some excess risk remains
unless the initial event was associated with a transient risk
factor. Thus, the net clinical benefit of prolonged VTE
prophylaxis depends on the risk of recurrent VTE versus
the risk of bleeding. Risk assessment tools are warranted to
support decision making, especially in severely ill patients
at high risk of hemorrhage [90].
From a research standpoint, a meta-analysis of individ-
ual patient data may theoretically provide novel informa-
tion, although there are substantial difficulties, including
time-consuming issues and technicalities to access original
data. We believe there are no specific areas requiring fur-
ther meta-analysis of RCTs, whereas ‘real-world’ data such
as well-designed observational studies could help in
resolving uncertainties surrounding safety issues, such as
liver injury and use in patients with renal impairment. A
recent tool is represented by post-authorization safety
studies (PASSs) and, in particular, specialist cohort event
monitoring (SCEM) studies enable a cohort of patients
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severe mitral  stenosis ‡ 
ClCr<15ml/min 
TTR > 70% on warfarin 
Electrical cardioversion 















D 110 No preference 








Consider HAS-BLED* (bleeding risk) 
Fig. 1 Simplified approach to guide selection among oral anticoag-
ulants. Asterisk If HAS-BLED C3, offer regular monitoring and
amend risk factors for bleeding in any patients initiating OACs. Hash
In patients with AF undergoing electrical cardioversion, VKAs
remain the standard of care, although available data suggest that
DOACs may be as safe and as effective. In patients undergoing
catheter ablation, uninterrupted warfarin is preferred in many
institutions [85, 86]. Double dragger For eligibility of DOACs in
specific valvular indications, please refer to the ESC guidelines [82].
Dragger Dose adjustment required, especially in patients aged
[80 years, body weight \60 kg, creatinine [1.5 mg/dl. For all
DOACs, please refer to the relevant summary of product character-
istics or product information to verify whether or not dose adjustment
is needed, including the extent of renal impairment and concomitant
use of P-glycoprotein inhibitors and/or CYP3A4 inhibitors. A apixa-
ban, D110 dabigatran 110 mg, DOAC direct-acting oral anticoagu-
lant, E edoxaban, OAC oral anticoagulant, R rivaroxaban, TTR time in
therapeutic range, VKA vitamin K antagonist, ClCr creatinine
clearance, GI gastrointestinal, ACS acute coronary syndrome, AF
atrial fibrillation, ESC European Society of Cardiology, CYP
cytochrome P450
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prescribed a medicine in secondary care to be monitored;
the Rivaroxaban Observational Safety Evaluation (ROSE)
study was requested by the EMA to monitor the short-term
(12-week) use and safety profile of rivaroxaban prescribed
for the prevention of stroke and systemic embolism in adult
patients with NVAF, treatment of DVT and PE, and pre-
vention of recurrent DVT and PE in adult patients requiring
anticoagulation [91]. Future observational studies should
be designed to investigate special populations (e.g. patients
with cancer or renal impairment) and newer agents such as
apixaban and edoxaban, provided that their uptake reaches
significant magnitude. In particular, for apixaban it is worth
verifying whether the theoretical advantage of less renal
clearance actually translates into actual clinical benefit in
patients with renal impairment [92, 93].
Among the various unsettled issues, the impact of
polypharmacy and drug–drug interactions is unclear and
warrant further investigation, especially in frail elderly
patients using DOACs in unconventional settings for
evolving therapeutic uses (e.g. heparin-induced thrombo-
cytopenia). In fact, although drug interactions are per-
ceived to be less likely with DOACs, compared with
VKAs, the precise incidence and significance of these
interactions remain to be clearly defined as the activity of
permeability glycoprotein (P-gp) varies greatly between
individuals. In particular, clinicians should be reminded of
the likelihood of interactions with drugs that inhibit both
P-gp and cytochrome P450 (CYP) 3A4 as some DOACs
(rivaroxaban, apixaban) are both substrates for P-gp and
metabolized extensively by CYP3A4 [94].
Taken together, our review calls for the need to move
from systematic reanalysis of the existent literature towards
a new era of evidence-based medicine. In particular, reg-
istry data from PASSs can optimistically fill our gap in
knowledge, especially considering the heterogeneity across
populations prospectively recorded in these inception
cohorts, which can be followed throughout a lifetime with
clinically useful laboratory and clinical data. Among these,
the Italian START-Register [95] was launched in 2011;
only 109 of 5252 patients received a DOAC due to the
relatively recent availability of drugs in the Italian market
and limitations of prescriptions by the Italian Regulatory
Agency. A number of global and country-specific registries
have been set up; apart from monitoring drug use, they can
provide a means of tracking uptake of guideline
recommendations.
Finally, evidence from pharmacovigilance analyses [i.e.
spontaneous reporting systems (SRSs)] should be carefully
considered; when properly designed with the intent of
addressing the actual safety profile in the postmarketing
phase, these studies offer additional complementary evi-
dence, compared with observational data and meta-analy-
ses, because they are likely to reflect real clinical practice,
where comorbidities, polypharmacotherapy and hetero-
geneity of diseases exist. Notably, international compar-
isons of adverse event reports highlighted that, for both
dabigatran and rivaroxaban, a large proportion of sponta-
neous reports (from 34 % up to 89 %) were associated with
the use of concomitant medicines with bleeding potential.
This highlights the need for active vigilance by prescribers
and the importance of assessing the patient’s comorbidity
and comedications to minimize risks in routine clinical
practice [96, 97].
The risk of liver injury associated with DOACs is a
recent safety issue (undetected in preclinical and clinical
phases), which only emerged from postmarketing analysis
of SRSs, especially for rivaroxaban [98]. Current data
suggest that most patients are characterized by a hepato-
cellular or mixed liver injury pattern, usually recovering
rapidly after drug discontinuation, although hepatic failure
has been reported. Overall, hepatotoxicity associated with
DOACs is idiosyncratic, appears at therapeutic doses and
cannot be explained by the pharmacological action of these
drugs. For rivaroxaban, currently available data are com-
patible with both an allergic and non-allergic (metabolic)
toxicity. Although incidence cannot be derived from SRSs,
the estimated frequency is clearly rarer compared with
ximelagatran; therefore, recommending close monitoring
of liver function in patients treated with DOACs is not
justified. However, the time to onset from published case
reports suggests that early evaluation of hepatic enzymes
(i.e. within the first month) may be considered, at least in
patients under complex treatment regimens with comor-
bidities; subsequently, liver function can be monitored on a
yearly basis [80]. Therefore, vigilance should be main-
tained by both clinicians, pharmacovigilance experts and
patients, who should timely communicate early clinical
signs/symptoms, consider on a case-by-case basis the role
of DOACs as well as concomitant therapies, and report
suspect cases to the national pharmacovigilance services
[99].
5 Summary and Perspectives
Potential overlapping studies exist comparing DOACs with
VKAs for consolidated therapeutic indications, namely
NVAF and VTE. The 44 systematic reviews retained in our
evidence-based review call for common criteria to reduce
redundant literature and facilitate both clinicians and reg-
ulators in the decision-making process. Overall, we can
confirm the comparable efficacy and effectiveness of
DOACs in comparison with VKAs in these consolidated
therapeutic indications. With regard to safety, systematic
reviews of RCTs and observational studies strongly agree
on the superiority of DOACs in terms of ICH, with similar
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data for gastrointestinal and major bleeding. However, no
direct head-to-head comparisons have been reported for the
four available DOACs, and individual choice among dif-
ferent drugs and doses is therefore challenging for clini-
cians [85, 86]. The agenda is rich of still unresolved
research issues (Table 3).
To address these challenging, unmet clinical needs,
comparative effectiveness and safety studies are warranted.
To date, only one Danish nationwide cohort study has
compared dabigatran, rivaroxaban and apixaban with
warfarin in patients with NVAF who were naı¨ve to oral
anticoagulants [100]. Apart from differential prescribing
patterns (with dabigatran preferentially used in younger
patients with a lower risk of stroke and less renal impair-
ment, likely to reflect perceived differences among DOACs
from preapproval trials), no significant differences have
emerged between DOACs and warfarin with regard to
ischemic stroke only; apixaban and dabigatran were asso-
ciated with a significantly lower risk of death and major
bleeding compared with rivaroxaban or warfarin (these last
Table 3 Key aspects still to be addressed
Research issues Comments
Overlapping systematic reviews The existence of actual redundant systematic reviews should be formally quantified. Future
systematic reviews must be consistently designed, registered and reported, especially by
reconciling the conclusions of prior reviews, along with a summary table of included studies
[75]
Actual risk of gastrointestinal bleeding
(magnitude and anatomical site)
This is especially the case for rivaroxaban, apixaban and edoxaban. For rivaroxaban, recent
postmarketing data identified possible increased risk, thus strengthening the importance of
minimizing modifiable risk factors [103]. It is also important to determine whether and how
upper gastrointestinal bleeding is influenced by the use of medications such as proton pump
inhibitors
Effectiveness and safety in special populations Elderly vulnerable patients with cancer should be closely monitored for adverse events
because they are at higher risk of bleeding complications. The use of DOACs in patients with
renal impairment is also debated (they are all excreted via the kidney, at least partially) and
insufficiently investigated. The 2015 EHRA practical guide suggested a 3-month interval
monitoring of renal function, using the Cockcroft–Gault method, in elderly patients [82]
Other safety issues beyond bleeding
complications
While, for coronary risk, recent data, including observational studies, are partially reassuring
[104], evidence on the risk of liver injury is accruing (case series and disproportionality
analysis) [98, 99]. With regard to renal injury, fewer data exist; a meta-analysis of ten RCTs
found no differences in the risk of renal failure (compared with VKAs), although
rivaroxaban showed a trend for increased risk and an increased risk of creatinine elevation
(RR 1.25, 95 % CI 1.08–1.45; I2 = 0 %) [25]
The impact of polypharmacy and drug–drug
interactions
Post-analyses of ROCKET-AF (rivaroxaban) and ARISTOTLE (apixaban) revealed that two-
thirds and three-quarters of patients had polypharmacy, respectively. This subgroup had a
higher risk of bleeding but not stroke (rivaroxaban), increased mortality, and higher rates of
thromboembolic and bleeding complications (apixaban) [105, 106]. The precise magnitude
and impact of drug–drug interactions requires database analysis in the near future, when the
use of DOACs reaches a plateau [94]
The need for measuring anticoagulant activity At the time of approval, no need for INR monitoring was promoted as a key advantage
favoring DOACs over VKAs. However, for both dabigatran and rivaroxaban, there is an
ongoing debate with regulators and companies on the actual importance of having laboratory
data as an early indicator of the efficacy/safety of the drug, especially in settings such as
polypharmacotherapy and emergency bleeding
The optimal incorporation of antidotes in
clinical practice
Idarucizumab is the only specific antidote designed to reverse the effect of dabigatran, licensed
by the EMA and US FDA in October 2015, but other antidotes are underway and will be
marketed in the near future for factor Xa inhibitors [107]. Cohort studies in ‘real-life’
conditions are warranted [108]
The existence of a cardiovascular protection
beyond anticoagulation
A subanalysis of RE-LY [109] showed that the use of dabigatran is associated with a reduction
in plasma apoB levels, although the underlying mechanism is only speculative
The risk–benefit profile in emerging arterial and
venous diseases
A number of trials are underway to test and confirm the efficacy and safety of DOACs in
emerging (cirrhosis, heparin-induced thrombocytopenia, antiphospholipid syndrome) and
evolving uses (patients with valvular heart disease, triple therapy, heart failure, catheter
ablation, electrical cardioversion) [102, 110]
EHRA European Heart Rhythm Association, RCTs randomized controlled trials, VKAs vitamin K antagonists, RR risk ratio, DOACs direct-acting
oral anticoagulants, INR international normalized ratio, EMA European Medicines Agency, FDA Food and Drug Administration, apoB
apolipoprotein B
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two drugs having similar profiles for bleeding risk). All
DOACs have lower rates of ICH than warfarin, but only
dabigatran consistently showed statistically significant
reduced risk in main and sensitivity analyses.
Current guidelines are incorporating emerging evidence
and, with minor differences, are recommending DOACs
over VKAs in several clinical scenarios. Only in a
minority of settings are VKAs preferred over DOACs, i.e.
patients with mechanical valves, time in therapeutic range
[70 % (provided that careful monitoring is maintained),
those with AF undergoing cardioversion or ablation, and
patients with AF on hemodialysis or with severe renal
impairment (Fig. 1). When choosing a particular type or
dose of DOAC, various clinical considerations can be
summarized by the mnemonic ‘ABCDE’: abnormally low
weight (dose reduction might be needed); bleeding risk,
especially previous or recent gastrointestinal bleeding;
creatinine clearance (i.e. renal function); drug interactions
(e.g. P-glycoprotein and/or CYP3A4 inhibitors); and
elderly age (dose reduction might be needed) [101].
Clarifying the potential role and proper use of DOACs in
these subgroups (i.e. actual contraindication or lack of
data) is a topic for further research. In addition, the
emerging use of DOACs in unconventional prothrombotic
settings (evolving and emerging indications) warrants
additional ‘real-world’ data [102]. In this context, PASSs
have started and country-specific registries are collecting
useful data.
6 Conclusions
Real-world data from observational studies are in line with
those from RCTs, and support the notion that, in NVAF
and VTE, DOACs are as effective as VKAs and safer in
terms of ICH. However, the actual benefit (or risk) in terms
of gastrointestinal bleeding still represents an unsolved
issue, which deserves head-to-head comparisons in the
real-world setting, especially in susceptible subpopulations
such as elderly patients, patients with cancer, and those
with multimorbidities (coexistence of NVAF with multi-
organ impairment) under polypharmacotherapy. Continued
monitoring by regulators, pharmacovigilance experts and
clinicians is mandatory.
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